DEA Clears This NASDAQ-Traded 'Plant-Touching' Firm To Research And Produce Schedule I And II Plant-Based Drugs
DEA Clears This NASDAQ-Traded 'Plant-Touching' Firm To Research And Produce Schedule I And II Plant-Based Drugs
Bright Green Corporation (NASDAQ:BGXX) announced on Thursday that it has received final approval from the New Mexico Board of Pharmacy and the DEA to register, license and authorize Schedule I and Schedule II plant-based drugs and active pharmaceutical ingredients for research, production, and manufacturing purposes.
Bright Green Corporation（納斯達克股票代碼：BGXX）週四宣佈，它已獲得新墨西哥州藥房委員會和美國藥物管理局的最終批准，可以註冊、許可和授權用於研究、生產和製造目的的附表一和附表二植物基藥物和活性藥物成分。
Schedule I substances include psilocybin, mescaline, peyote and ibogaine, while schedule II substances include opium, poppy straw, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, opium straw concentrates, alongside pending: erythroxylon coca (cocaine).
附表一物質包括迷幻藥、美斯卡林、peyote和ibogaine，而附表二的物質包括鴉片、罌粟秸稈、生鴉片、鴉片提取物、鴉片粉、鴉片顆粒、鴉片酊劑、鴉片液體提取物、鴉片秸稈濃縮物，以及待定的：赤黴素古柯（可卡因）。
The research will be conducted by the company's C2 team in Albuquerque, New Mexico, and the reshoring of production and manufacturing to the U.S. will take place at its Grants, New Mexico facility.
該研究將由該公司位於新墨西哥州阿爾伯克基的C2團隊進行，並將生產和製造轉移到美國，將在其位於新墨西哥州的格蘭茨工廠進行。
See also: DEA-Endorsed Cannabis Grower Makes History As First 'Plant-Touching' Firm On NASDAQ, Shares Soared
另見：美國緝毒局認可的大麻種植者創造了歷史，成爲納斯達克首家 “觸摸植物” 的公司，股價飆升
The latest update builds the company registering its federal license with the DEA for the cultivation, manufacture and sale of cannabis and cannabis-related products for research and pharmaceutical applications under federal and state law, previously.
最新的更新表明，該公司先前根據聯邦和州法律向美國藥物管理局註冊了用於研究和製藥應用的大麻和大麻相關產品的聯邦許可證。
Why It Matters
爲什麼重要
The company said, that the latest approval enables it to propel its 'Drugs Made in America' movement forward.
該公司表示，最新的批准使其能夠推動 “美國製造的藥品” 向前發展。
The effort is expected to help address the supply chain shortage for plant-based medicines.
預計這項工作將有助於解決植物性藥物的供應鏈短缺問題。
What's Next
下一步是什麼
Groovy Singh, CEO of Bright Green, talked about what's next for the company.
Bright Green首席執行官Groovy Singh談到了該公司的下一步發展。
"As we undergo an expansion of our infrastructure, we plan to leverage the capital to be raised from our exclusive EB-5 partnership with Asia Capital Pioneers Group, as well as funding from federal agencies," Singh explained. "The modular design of our facilities positions us to scale with demand and ensure that as production grows, so does our capacity to create jobs in direct correlation with EB-5 capital availability in a methodical phased approach."
辛格解釋說：“隨着基礎設施的擴張，我們計劃利用與亞洲資本先鋒集團的獨家EB-5合作伙伴關係籌集的資金，以及來自聯邦機構的資助。”“我們設施的模塊化設計使我們能夠根據需求進行擴展，並確保隨着產量的增長，我們以有條不紊的分階段方法創造就業機會的能力也與EB-5資本可用性直接相關。”
Now read: DEA-Licensed Cannabis Producer Bright Green Closes $3.5M Private Placement
立即閱讀：美國緝毒局許可的大麻生產商Bright Green完成350萬美元的私募配售
BGXX Price Action
BGXX 價格走勢
Bright Green Corp.'s shares traded 4.5222% lower at $0.2238 per share at the time of writing on Friday.
亮綠色公司'截至週五撰寫本文時，s股下跌4.5222％，至每股0.2238美元。
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
本辛加大麻資本會議將於2024年4月16日和17日在佛羅里達州好萊塢的新地點重返佛羅里達州。在外交官海灘度假村舉行的爲期兩天的活動將爲大小企業家提供交流、學習和成長的機會。這次會議以其引領潮流的能力和對大麻未來的影響而聞名，記住你的日曆——這是大麻界年度必去的活動。
Get your tickets now on bzcannabis.com – Prices will increase very soon!
立即在bzcannabis.com上購買門票——價格很快就會上漲！
Photo: Courtesy of Ousa Chea on Unsplash
照片：由 Unsplash 上的 Ousa Chea 提供
譯文內容由第三人軟體翻譯。